JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Начало・Списък с акции・Cytek Biosciences Inc

Cytek Biosciences Inc

Затворен

СекторЗдравеопазване

4.42 -3.49

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.35

Максимум

4.55

Ключови измерители
By Trading Economics
Приходи	-39M -44M
Продажби	9.8M 62M
Марж на печалбата	-70.929
Служители	702
EBITDA	4M -263K

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+40.13% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	12M 573M
Предишно отваряне	7.91
Предишно затваряне	4.42

Настроения в новините

By Acuity

50%

177 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

3.7 / 3.8 Подкрепа & съпротива

Cytek Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

28.04.2026 г., 23:33 ч. UTC

Горещи акции

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28.04.2026 г., 23:24 ч. UTC

Печалби

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28.04.2026 г., 23:15 ч. UTC

Значими събития в новините

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28.04.2026 г., 22:46 ч. UTC

Печалби

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28.04.2026 г., 22:37 ч. UTC

Печалби

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28.04.2026 г., 22:15 ч. UTC

Печалби

Значими събития в новините

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28.04.2026 г., 23:33 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28.04.2026 г., 23:31 ч. UTC

Печалби

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28.04.2026 г., 23:31 ч. UTC

Печалби

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28.04.2026 г., 23:30 ч. UTC

Печалби

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28.04.2026 г., 23:30 ч. UTC

Печалби

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28.04.2026 г., 23:19 ч. UTC

Пазарно говорене

Печалби

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28.04.2026 г., 23:09 ч. UTC

Печалби

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28.04.2026 г., 23:03 ч. UTC

Пазарно говорене

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR Sees One Rate Rise to 4% in Benign Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28.04.2026 г., 23:01 ч. UTC

Значими събития в новините

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28.04.2026 г., 22:51 ч. UTC

Печалби

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28.04.2026 г., 22:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

28.04.2026 г., 22:48 ч. UTC

Пазарно говорене

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28.04.2026 г., 22:40 ч. UTC

Пазарно говорене

Значими събития в новините

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28.04.2026 г., 22:32 ч. UTC

Печалби

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28.04.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28.04.2026 г., 22:22 ч. UTC

Печалби

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28.04.2026 г., 22:17 ч. UTC

Пазарно говорене

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28.04.2026 г., 22:14 ч. UTC

Печалби

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28.04.2026 г., 22:14 ч. UTC

Печалби

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28.04.2026 г., 22:07 ч. UTC

Пазарно говорене

Значими събития в новините

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Cytek Biosciences Inc Прогноза

Ценова цел

By TipRanks

40.13% нагоре

12-месечна прогноза

Среден 6.25 USD 40.13%

Висок 7.5 USD

Нисък 5 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Cytek Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Cytek Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

3.7 / 3.8Подкрепа & съпротива

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

177 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.